November 12, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating new side effect risks for Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) and AstraZeneca’s EGFR inhibitor Tagrisso (osimertinib), a move likely to trigger a label change in the near future. According to...read more